These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 15574623)

  • 1. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
    Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.